Trial
NCT02452424
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Daiichi Sankyo
Collaborators
Plexxikon; Merck Sharp & Dohme LLC
Condition
Melanoma
Intervention
PLX3397
Why stopped
Terminated early for insufficient evidence of clinical efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-05